QUINTESSENTIAL: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 15, 2026 - P2 | N=230 | Recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Trial primary completion date: Jun 2027 ➔ Jul 2026
Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
|